1. European recommendations for antimicrobial resistance surveillance
G. Cornaglia, W. Hryniewicz, V. Jarlier, G. Kahlmeter, H. Mittermayer, L. Stratchounski, F. Baquero 
Clinical Microbiology and Infection 
Volume 10, Issue 4, Pages (April 2004)
DOI: /j X x
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Ciprofloxacin MIC distribution for wild-type Escherichia coli, as obtained by means of the EUCAST web-based program ‘Antimicrobial wild-type distributions of microorganisms’ ( Data (4416 observations) were pooled from six sources, such as breakpoint committees, surveillance programmes, the pharmaceutical industry and scientific reports. Epidemiological cut-off: WT ≤ mg/L.
Clinical Microbiology and Infection  , DOI: ( /j X x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
Streptococcus pneumoniae isolates vs. erythromycin from data collected by the EARSS in The erythromycin S/I breakpoints used by countries involved in the EARSS were S < 0, 5, 1 and 2 mg/L, while the I/R breakpoints were R > 0.5, 1, 2 and 4 mg/L.
Clinical Microbiology and Infection  , DOI: ( /j X x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions